1. Hamady ZZ, Scott N, Farrar MD, et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut. 2010; 59:461–469.

2. Kim JM. Inflammatory bowel diseases and enteric microbiota. Korean J Gastroenterol. 2010; 55:4–18.

3. Wehkamp J, Wang G, Kü bler I, et al. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4. J Immunol. 2007; 179:3109–3118.

4. Palmer CD, Rahman FZ, Sewell GW, et al. Diminished mac-rophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn's disease. PLoS One. 2009; 4:e7787.

5. Cooney R, Baker J, Brain O, et al. NOD2 stimulation in-duces autophagy in dendritic cells influencing bacterial han-dling and antigen presentation. Nat Med. 2010; 16:90–97.

6. UK IBD Genetics Consortium. Barrett JC, Lee JC, et al. Genomewide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009; 41:1330–1334.

7. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Longterm antibiotic treatment for Crohn's disease: systematic review and metaanalysis of placebo-controlled trials. Clin Infect Dis. 2010; 50:473–480.

8. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006; 55:205–211.

9. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium iden-tified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008; 105:16731–16736.

10. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CG. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA. 2007; 104:7617–7621.

11. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria reg-ulate intestinal epithelial cell survival and growth. Gastroenterology. 2007; 132:562–575.

12. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral me-salamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003; 349:350–357.

13. Matsuura M, Okazaki K, Nishio A, et al. Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology. 2005; 128:975–986.

14. Arrieta MC, Madsen K, Doyle J, Meddings J. Reducing small intestinal permeability attenuates colitis in the IL10 gene-defi-cient mouse. Gut. 2009; 58:41–48.

15. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment Pharmacol Ther. 2003; 17:1355–1364.